Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Cash and cash equivalents consisted of the following (in thousands):

	March 31, 2016		December 31, 2015
Cash	$	96,198	$	75,685
Money market funds		44,761		77,639
Total cash and cash equivalents	$	140,959	$	153,324

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments

All investments are classified as available-for-sale. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands):

	March 31, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	125,825	$	529	$	(75	)	$	126,279
Certificate of deposits		2,241		—		—			2,241
Bond and mutual funds		25,712		—		—			25,712
Equity investments		126		105		—			231
Total investments	$	153,904	$	634	$	(75	)	$	154,463

	December 31, 2015
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	126,522	$	54	$	(473	)	$	126,103
Certificate of deposits		8,217		—		(2	)		8,215
Bond and mutual funds		25,052		—		—			25,052
Equity investments		126		71		—			197
Total investments	$	159,917	$	125	$	(475	)	$	159,567

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2016		December 31, 2015
Preclinical and clinical trial accruals	$	29,023	$	27,973
Payroll and related accruals		9,511		13,535
Professional services		1,338		1,662
Other		4,166		4,762
Total accrued liabilities	$	44,038	$	47,932